Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Verified date | October 2021 |
Source | Amgen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized phase 2 trial is studying the effect of adding denosumab to standard chemotherapy in the treatment of advanced lung cancer.
Status | Completed |
Enrollment | 226 |
Est. completion date | November 28, 2017 |
Est. primary completion date | July 29, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: - Histologically or cytologically confirmed stage IV non-small cell lung carcinoma (NSCLC), according to 7th Tumor/Node/Metastasis (TNM) classification (cytological specimens obtained by bronchial washing or brushing, or fine-needle aspiration are acceptable) - Subject has available and has provided consent to release to the sponsor (or designee) a tumor block with confirmed tumor content (or approximately 20 unstained charged slides [a minimum of 7 slides is mandatory]) and the corresponding pathology report - Planned to receive 4 to 6 cycles of pemetrexed or gemcitabine in combination with cisplatin or carboplatin • For subjects to receive pemetrexed, planned to receive vitamin B12 and folate per pemetrexed approved labeling - Radiographically evaluable (measurable or non-measurable) disease (according to modified Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria - Other inclusion criteria may apply Exclusion Criteria: - Known presence of documented sensitizing epidermal growth factor receptor (EGFR) activating mutation or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation (screening following local standards, but strongly encouraged in non-squamous histology) - Known brain metastases (systematic screening of patients not mandatory) - Any prior systemic therapy (before randomization) for the treatment of NSCLC (including chemoradiation), except if for non-metastatic disease and was completed at least 6 months prior to randomization - Planned to receive bevacizumab - Significant dental/oral disease, including prior history or current evidence of osteonecrosis/ osteomyelitis of the jaw, or with the following: - Active dental or jaw condition which requires oral surgery - Non-healed dental/oral surgery - Planned invasive dental procedures for the course of the study. |
Country | Name | City | State |
---|---|---|---|
Australia | Research Site | Adelaide | South Australia |
Australia | Research Site | Footscray | Victoria |
Australia | Research Site | Kogarah | New South Wales |
Australia | Research Site | Parkville | Victoria |
Australia | Research Site | Wahroonga | New South Wales |
Australia | Research Site | Wodonga | Victoria |
Canada | Research Site | Edmonton | Alberta |
Canada | Research Site | Kitchener | Ontario |
Canada | Research Site | Montreal | Quebec |
Canada | Research Site | Saint John | New Brunswick |
Canada | Research Site | Sudbury | Ontario |
Canada | Research Site | Toronto | Ontario |
Canada | Research Site | Toronto | Ontario |
Czechia | Research Site | Chomutov | |
Czechia | Research Site | Ostrava-Poruba | |
Czechia | Research Site | Pardubice | |
Czechia | Research Site | Praha 8 | |
Czechia | Research Site | Usti nad Labem | |
France | Research Site | Caen Cedex 5 | |
France | Research Site | Dijon cedex | |
France | Research Site | Nantes Cedex 2 | |
France | Research Site | Paris Cedex 10 | |
France | Research Site | Paris Cedex 14 | |
France | Research Site | Paris Cedex 20 | |
France | Research Site | Pessac Cedex | |
France | Research Site | Reims Cedex | |
France | Research Site | Saint Quentin | |
France | Research Site | Tours Cedex 9 | |
Germany | Research Site | Berlin | |
Germany | Research Site | Grosshansdorf | |
Germany | Research Site | Köln-Merheim | |
Germany | Research Site | Ulm | |
Greece | Research Site | Athens | |
Greece | Research Site | Athens | |
Greece | Research Site | Heraklion | |
Greece | Research Site | Patra | |
Greece | Research Site | Thessaloniki | |
Greece | Research Site | Thessaloniki | |
Italy | Research Site | Monza (MB) | |
Italy | Research Site | Orbassano (TO) | |
Italy | Research Site | Pavia | |
Italy | Research Site | Roma | |
Italy | Research Site | Saronno VA | |
Netherlands | Research Site | 's Hertogenbosch | |
Netherlands | Research Site | Arnhem | |
Netherlands | Research Site | Harderwijk | |
Netherlands | Research Site | Tilburg | |
Netherlands | Research Site | Zutphen | |
United Kingdom | Research Site | Bristol | |
United Kingdom | Research Site | Exeter | |
United Kingdom | Research Site | Glasgow | |
United Kingdom | Research Site | Guildford | |
United Kingdom | Research Site | London | |
United Kingdom | Research Site | London | |
United Kingdom | Research Site | Plymouth | |
United Kingdom | Research Site | Preston | |
United States | Research Site | Alexandria | Louisiana |
United States | Research Site | Anaheim | California |
United States | Research Site | Bismarck | North Dakota |
United States | Research Site | Brewer | Maine |
United States | Research Site | Cincinnati | Ohio |
United States | Research Site | Detroit | Michigan |
United States | Research Site | Durham | North Carolina |
United States | Research Site | East Setauket | New York |
United States | Research Site | Fairhaven | Massachusetts |
United States | Research Site | Farmington | Connecticut |
United States | Research Site | Goodyear | Arizona |
United States | Research Site | Hickory | North Carolina |
United States | Research Site | Long Beach | California |
United States | Research Site | Los Angeles | California |
United States | Research Site | Los Angeles | California |
United States | Research Site | Nashville | Tennessee |
United States | Research Site | Westminster | Maryland |
United States | Research Site | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Amgen |
United States, Australia, Canada, Czechia, France, Germany, Greece, Italy, Netherlands, United Kingdom,
Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe HS, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Barneto Aranda I, Scherz A, Tsourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, O'Brien M. Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. Lung Cancer. 2021 Nov;161:76-85. doi: 10.1016/j.lungcan.2021.09.002. Epub 2021 Sep 9. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Survival (OS) | Overall survival was calculated as the time from the date of randomization to the date of death from any cause. Participants last known to be alive were censored at the last contact date. | From randomization until the end of study; median time on study was 9.64 months. | |
Secondary | Correlation of Tumor Tissue RANK Expression With Overall Survival | To assess whether the treatment effect on overall survival was correlated with receptor activator of nuclear factor (NF)-?B (RANK) protein expression in tumor cells, RANK expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm, membrane, and total was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANK expression level and OS was evaluated using a Cox proportional hazard models that included RANK expression level stratified by the randomization stratification factors in the corresponding treatment group. |
From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months. | |
Secondary | Correlation of Tumor Tissue RANK Ligand Expression With Overall Survival | To assess whether the treatment effect on overall survival was correlated with RANK ligand (RANKL) protein expression in tumor cells, RANKL expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANKL expression level and OS was evaluated using a Cox proportional hazard models that included RANKL expression level stratified by the randomization stratification factors in the corresponding treatment group. |
From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months. | |
Secondary | Objective Response Rate | Objective response rate was defined as the percentage of participants with a complete response (CR) or partial response (PR) based on modified RECIST 1.1 achieved over the study duration. CR: Disappearance of all target and non target lesions, normalization of tumor marker levels and no new lesions. PR: At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, disappearance of target lesions with persistence of one or more non-target lesions and/or maintenance of tumor marker levels above normal limits and no new lesions. Participants who underwent surgical resection while on study were not evaluated for response after the surgery. Participants who did not meet the criteria for an objective response by the analysis cutoff date were considered non-responders. |
From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months. | |
Secondary | Correlation of Tumor Tissue RANK Expression With Objective Response Rate | To assess whether the treatment effect on objective response rate (ORR) based on RECIST 1.1 was correlated with RANK protein expression in tumor cells, RANK expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm, membrane, and total was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANK expression level and ORR was evaluated within each treatment group using a logistical regression model that included RANK expression value as an independent variable and stratified by the randomization stratification factors. The odds ratio and 95% confidence interval are reported. |
From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months. | |
Secondary | Correlation of Tumor Tissue RANKL Expression With Objective Response Rate | To assess whether the treatment effect on objective response rate (ORR) based on RECIST 1.1 was correlated with RANKL protein expression in tumor cells, RANKL expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity. The correlation between RANKL expression level and ORR was evaluated within each treatment group using a logistical regression model that included RANKL expression value as an independent variable and stratified by the randomization stratification factors. The odds ratio and 95% confidence interval are reported. |
From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months. | |
Secondary | Clinical Benefit Rate | Clinical benefit rate was defined as the percentage of participants with an objective response (CR or PR) or stable disease (SD) or better for at least 16 weeks achieved over the study duration. If a participant underwent surgical resection while on study, the participant was not evaluated for response after the surgery. Participants who did not meet the criteria for clinical benefit by the analysis cutoff date were considered as non-responders. | From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months. | |
Secondary | Progression-free Survival (PFS) | Progression-free survival was defined as the time from randomization to the first observed disease progression per modified RECIST 1.1 criteria or death from any cause. Participants last known to be alive who did not experience disease progression were censored at their last imaging assessment date, last contact date if they were in the survival follow up phase, end of the study date, or the primary analysis cut-off date, whichever was first. If a participant underwent surgical resection while on study, the participant was censored at the last evaluable imaging assessment prior to the surgery. | From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months. | |
Secondary | Serum Denosumab Trough Levels in Participants Who Received Q3W Dosing | Serum samples were analyzed for denosumab using enzyme-linked immunosorbent assay (ELISA) following a validated procedure. The lower limit of quantification for the assay was 20 ng/mL. | Prior to dosing at day 8 and weeks 3, 6, 9, 12, 15, 18, 21 and 24. | |
Secondary | Serum Denosumab Trough Levels in Participants Who Received Q4W Dosing | Serum samples were analyzed for denosumab using enzyme-linked immunosorbent assay (ELISA) following a validated procedure. The lower limit of quantification for the assay was 20 ng/mL. | Prior to dosing at day 8 and weeks 4, 8, 12, 16, 20 and 24 | |
Secondary | Number of Participants With Treatment-emergent Adverse Events | An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an AE that meets at least 1 of the following criteria fatal life threatening requires in-patient hospitalization or prolongation of existing hospitalization results in persistent or significant disability/incapacity congenital anomaly/birth defect other medically important serious event Treatment-related AEs include only TEAEs for which the investigator indicated there was a reasonable possibility they may have been caused by study drug. Fatal adverse events include only deaths reported on the Adverse Event Case Report Form. |
From first dose of study drug to the end of study date; the median (min, max) duration was 10.0 (0.2, 41.4) and 9.4 (0.2, 42.9) months for Placebo and Denosumab respectively. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |